Skip to main content

. 1982 Apr;13(4):571–574. doi: 10.1111/j.1365-2125.1982.tb01424.x

Early kinetics of intravenous propranolol.

T C Fagan, T Walle, U K Walle, E C Conradi, G Harmon, T E Gaffney

PMCID: PMC1402040 PMID: 7066173

571

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Hesse B., Hansen J. F., Steiness E., Ehlers D., Andersen J. D. Temporal relationship between cardiac performance and myocardial uptake of dl-propranolol in man. Clin Exp Pharmacol Physiol. 1979 May-Jun;6(3):241–248. doi: 10.1111/j.1440-1681.1979.tb01245.x. [DOI] [PubMed] [Google Scholar]
Kates R. E., Jaillon P. A model to describe myocardial drug disposition in the dog. J Pharmacol Exp Ther. 1980 Jul;214(1):31–36. [PubMed] [Google Scholar]
Loo J. C., Riegelman S. Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion. J Pharm Sci. 1970 Jan;59(1):53–55. doi: 10.1002/jps.2600590107. [DOI] [PubMed] [Google Scholar]
Pruett J. K., Walle T., Bagwell E. E. Association of in vivo and in vitro propranolol levels in canine Purkinje fibers with antiarrhythmic effects. J Pharmacol Exp Ther. 1977 Jul;202(1):45–54. [PubMed] [Google Scholar]
Riva E., Latini R., Cremonesi A., Zacà F., Pagliarani P. Time course of plasma levels and electrophysiologic effects of propranolol in man. J Cardiovasc Pharmacol. 1980 Nov-Dec;2(6):707–714. doi: 10.1097/00005344-198011000-00001. [DOI] [PubMed] [Google Scholar]
Routledge P. A., Shand D. G. Clinical pharmacokinetics of propranolol. Clin Pharmacokinet. 1979 Mar-Apr;4(2):73–90. doi: 10.2165/00003088-197904020-00001. [DOI] [PubMed] [Google Scholar]
Schamroth L. Immediate effects of intravenous propranolol on various cardiac arrhythmias. Am J Cardiol. 1966 Sep;18(3):438–443. doi: 10.1016/0002-9149(66)90067-1. [DOI] [PubMed] [Google Scholar]
Walle T., Conradi E. C., Walle U. K., Fagan T. C., Gaffney T. E. 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol. Clin Pharmacol Ther. 1980 Jan;27(1):22–31. doi: 10.1038/clpt.1980.4. [DOI] [PubMed] [Google Scholar]
Walle T., Conradi E. C., Walle U. K., Fagan T. C., Gaffney T. E. Naphthoxylactic acid after single and long-term doses of propranolol. Clin Pharmacol Ther. 1979 Nov;26(5):548–554. doi: 10.1002/cpt1979265548. [DOI] [PubMed] [Google Scholar]
Walle T., Conradi E. C., Walle U. K., Fagan T. C., Gaffney T. E. The predictable relationship between plasma levels and dose during chronic propranolol therapy. Clin Pharmacol Ther. 1978 Dec;24(6):668–677. doi: 10.1002/cpt1978246668. [DOI] [PubMed] [Google Scholar]
Walle T., Fagan T. C., Conradi E. C., Walle U. K., Gaffney T. E. Presystemic and systemic glucuronidation of propranolol. Clin Pharmacol Ther. 1979 Aug;26(2):167–172. doi: 10.1002/cpt1979262167. [DOI] [PubMed] [Google Scholar]
Wood M., Shand D. G., Wood A. J. Altered drug binding due to the use of indwelling heparinized cannulas (heparin lock) for sampling. Clin Pharmacol Ther. 1979 Jan;25(1):103–107. doi: 10.1002/cpt1979251103. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES